MwanzoIMC • ASX
add
Immuron Ltd
Bei iliyotangulia
$ 0.077
Bei za mwaka
$ 0.065 - $ 0.17
Thamani ya kampuni katika soko
16.53M AUD
Wastani wa hisa zilizouzwa
elfu 124.23
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
ASX
Habari za soko
TipRanks
saa 4 zilizopita
Microsoft (NASDAQ:MSFT) Stock: Turn the Dip into a Golden Buying Opportunity
1.17%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (AUD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.27M | 108.61% |
Matumizi ya uendeshaji wa biashara | 2.56M | 79.40% |
Mapato halisi | -2.43M | -169.00% |
Kiwango cha faida halisi | -190.94 | -28.94% |
Mapato kwa kila hisa | — | — |
EBITDA | -1.68M | -118.52% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (AUD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 11.66M | -32.07% |
Jumla ya mali | 15.55M | -29.28% |
Jumla ya dhima | 2.84M | 19.79% |
Jumla ya hisa | 12.71M | — |
hisa zilizosalia | 228.00M | — |
Uwiano wa bei na thamani | 1.28 | — |
Faida inayotokana na mali | -27.02% | — |
Faida inayotokana mtaji | -32.61% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (AUD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -2.43M | -169.00% |
Pesa kutokana na shughuli | -1.94M | -141.79% |
Pesa kutokana na uwekezaji | elfu 87.03 | 1,082.80% |
Pesa kutokana na ufadhili | elfu 12.00 | 203.57% |
Mabadiliko halisi ya pesa taslimu | -1.78M | -170.36% |
Mtiririko huru wa pesa | -1.03M | -197.20% |
Kuhusu
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Ilianzishwa
1994
Makao Makuu
Tovuti
Wafanyakazi
7
